Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study Evaluating Combination Therapy With the Receptor Tyrosine Kinase Inhibitor PLX3397 and Sirolimus in Patients With Unresectable Sarcoma and Phase II Study in Malignant Peripheral Nerve Sheath Tumors

Next Previous
Trial Profile

Phase I Study Evaluating Combination Therapy With the Receptor Tyrosine Kinase Inhibitor PLX3397 and Sirolimus in Patients With Unresectable Sarcoma and Phase II Study in Malignant Peripheral Nerve Sheath Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pexidartinib (Primary) ; Sirolimus
  • Indications Angiomyolipoma; Gastrointestinal stromal tumours; Giant cell tumour of tendon sheath; Leiomyosarcoma; Meningioma; Nerve sheath neoplasms; Sarcoma; Soft tissue sarcoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms PLX3397

    • Most Recent Events

    • 12 Mar 2024 Planned End Date changed from 1 Mar 2024 to 1 Jun 2024.
    • 12 Mar 2024 Status changed from recruiting to active, no longer recruiting.
    • 16 Feb 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Jul 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top